6 recruiting, 5 completed, 3 withdrawn, 2 active not recruiting. 9 Phase 2, 6 Phase 1, 2 Not applicable, 1 Early Phase 1.
Follow Immunoconjugates: new trials by email Literature Review of Immunoconjugates trials Research Report on Immunoconjugates
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates scalp cooling, photographs via the Belle.AI app, Antibody-Drug Conjugates - Advanced or Metastatic Solid Tumour, Antibody-Drug Conjugate | Phase 2 | Not yet recruiting | Jules Bordet Institute | 102 | 2026-09-01 | 2026-08-19 |
| Imaging of Solid Tumors Using DLL3 SPECT 111In-ABD147, Single-photon emission computed tomography (SPECT)/Computerized tomography (CT) - Solid Tumor Cancer, Castration Resistant Prostate Cancer | Early Phase 1 | Withdrawn | Thomas Hope | 2026-04-30 | 2026-04-29 | |
| Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids Antibody-drug conjugate (ADC) combination therapy - HER2 Positive OR TROP2 Positive Non-Small Cell Lung Cancer | Recruiting | Guangzhou Institute of Respiratory Disease | 10 | 2025-12-28 | 2026-05-28 | |
| Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies Bispecific antibody, Antibody-Drug Conjugate, Monoclonal antibody - Multiple Myeloma, Relapsed, Multiple Myeloma (MM) | Recruiting | Sung-Soo Park | 174 | 2025-07-14 | 2025-07-15 | |
| Optimal Application Timing of ADC Drugs for Advanced Breast Cancer Antibody drug conjugate, Chemotherapy - Breast Cancer Females | Phase 2 | Recruiting | Liaoning Cancer Hospital & Institute | 120 | 2025-07-01 | 2026-06-18 |
| First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma Antibody-drug conjugate (ADC) - Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma | Phase 1 / Phase 2 | Recruiting | Adcendo ApS | 270 | 2025-06-05 | 2026-09-11 |
| Immunotherapy in Lymphoma CAR-T Therapy, Bispecific antibody, Antibody-Drug Conjugate - Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma | Recruiting | Sung-Soo Park | 72 | 2024-06-26 | 2025-01-28 | |
| Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors Antibody-Drug Conjugate - Cancer | Phase 1 / Phase 2 | Recruiting | MBrace Therapeutics | 130 | 2023-11-07 | 2026-03-02 |
| Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan Antibody-Drug Conjugates - Breast Cancer, Metastatic Cancer | Completed | Hellenic Cooperative Oncology Group | 312 | 2023-01-01 | 2025-09-15 | |
| Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities Antibody-Drug Conjugate, Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate - Sepsis (SMQ), Opportunistic Infections | Completed | Central South University | 24618 | 2022-04-22 | 2022-06-22 | |
| FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer FOR46, Enzalutamide, Pegfilgrastim - Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | Rahul Aggarwal | 44 | 2022-01-19 | 2026-09-17 |
| ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) ARX788 - HER2 Positive Metastatic Breast Cancer | Phase 2 | Active not recruiting | Ambrx, Inc. | 72 | 2021-10-26 | 2026-03-09 |
| MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma Dose Escalation, MEDI2228, ADC (antibody drug conjugate), Dose Expansion, MEDI2228, ADC (antibody drug conjugate) - Relapsed/Refractory Multiple Myeloma | Phase 1 | Completed | MedImmune LLC | 107 | 2018-05-08 | 2022-03-28 |
| A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01) ARX788 - Breast Neoplasms, Gastric Neoplasm | Phase 1 | Completed | Ambrx, Inc. | 106 | 2018-03-20 | 2024-02-01 |
| Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer Palbociclib, Trastuzumab, Endocrine therapy - Metastatic Breast Cancer | Phase 2 | Completed | SOLTI Breast Cancer Research Group | 73 | 2015-07-01 | 2024-04-18 |
| Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 Brentuximab vedotin - Peripheral T-Cell Lymphoma | Not applicable | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 1 | 2014-04-01 | 2017-01-19 |
| A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer IMMU 130 - Metastatic Colorectal Cancer | Phase 2 | Withdrawn | Gilead Sciences | 2013-09-01 | 2021-08-19 | |
| Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly brentuximab vedotin - Lymphoma | Not applicable | Withdrawn | H. Lee Moffitt Cancer Center and Research Institute | 2013-03-01 | 2013-07-25 | |
| Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer Labetuzumab Govitecan (LG) - Metastatic Colorectal Cancer, Colon Cancer | Phase 1 / Phase 2 | Terminated | Gilead Sciences | 92 | 2013-02-12 | 2024-01-24 |
Breast Neoplasms (5) · Recurrence (4) · Colorectal Neoplasms (2) · Multiple Myeloma (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Rectal Neoplasms (2) · Agranulocytosis (1) · Alopecia (1) · Brain Neoplasms (1) · Burkitt Lymphoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Lymphoma (1) · Lymphoma, B-Cell (1)
Ambrx, Inc. (2) · Gilead Sciences (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Sung-Soo Park (2) · Adcendo ApS (1) · Central South University (1) · Guangzhou Institute of Respiratory Disease (1) · Hellenic Cooperative Oncology Group (1) · Jules Bordet Institute (1) · Liaoning Cancer Hospital & Institute (1) · MBrace Therapeutics (1) · MedImmune LLC (1) · Rahul Aggarwal (1) · SOLTI Breast Cancer Research Group (1) · Thomas Hope (1)
United States (8) · Australia (3) · China (3) · South Korea (3) · Belgium (2) · Greece (2) · Spain (2) · France (1) · Germany (1) · United Kingdom (1)
Lubomir Sokol, M.D., Ph.D. (2) · Bo Lan (1) · Chengzhi Zhou, PhD (1) · Eva Ciruelos, MD (1) · Evandro de Azambuja, MD PhD (1) · Rahul Aggarwal, MD (1) · Tao Sun (1) · Thomas A Hope, MD (1)
PMID 30859213, PMID 33369581, PMID 34358100, PMID 35318309, PMID 38028985, PMID 40662373
2014 (1)